$ZIVO
Zivo Bioscience, Inc. Stock $zivo

$zivo Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000165495422010607 Filed on August 04, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00	$0.00
YoY Change
Gross Profit	$0.00	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.397M	$1.630M	$1.347M
YoY Change	10.57%	27.16%	-6.27%
% of Gross Profit
Research & Development	$603.1K	$438.0K	$679.8K
YoY Change	-23.89%	-6.38%	5.11%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.000M	$2.068M	$2.027M
YoY Change	-2.72%	18.19%	-2.74%
Operating Profit	-$2.000M	-$2.068M	-$2.027M
YoY Change	-2.72%	18.19%
Interest Expense	$4.245K	$4.238K	$1.805K
YoY Change	1921.43%	-77.19%	-92.62%
% of Operating Profit
Other Income/Expense, Net	-$4.245K	$4.238K	-$1.805K
YoY Change	-103.49%	-95.6%	-98.67%
Pretax Income	-$2.004M	-$2.072M	-$2.028M
YoY Change	26.51%	12.26%	-8.59%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$2.004M	-$2.072M	-$2.028M
YoY Change	3.61%	12.26%	-8.59%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$212.8K	-$219.9K	-$215.3K
COMMON SHARES
Basic Shares Outstanding	9.420M shares	9.420M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.386M	$5.084M	$6.599M
YoY Change	-68.66%	-53.37%	2745.12%
Cash & Equivalents	$3.386M	$5.084M	$6.599M
Short-Term Investments
Other Short-Term Assets	$342.6K	$517.1K	$855.3K
YoY Change	159.35%	226.01%	277.68%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$3.729M	$5.601M	$7.454M
YoY Change	-65.9%	-49.37%	1526.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$0.00	$0.00
YoY Change			-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$242.8K	$263.8K	$233.9K
YoY Change	572.49%	531.98%	22.78%
TOTAL ASSETS
Total Short-Term Assets	$3.729M	$5.601M	$7.454M
Total Long-Term Assets	$242.8K	$263.8K	$233.9K
Total Assets	$3.971M	$5.865M	$7.688M
YoY Change	-63.8%	-47.18%	1084.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$607.0K	$407.8K	$520.4K
YoY Change	-16.72%	-55.59%	-70.01%
Accrued Expenses	$364.8K	$631.9K	$301.8K
YoY Change	-15.43%	137.18%	-89.47%
Deferred Revenue
YoY Change
Short-Term Debt	$139.7K	$349.2K	$558.8K
YoY Change		449.95%	252.2%
Long-Term Debt Due	$240.0K	$240.0K	$240.0K
YoY Change	0.0%	0.0%	-95.37%
Total Short-Term Liabilities	$2.315M	$2.697M	$2.959M
YoY Change	-34.74%	-25.95%	-75.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$131.9K	$157.0K	$144.1K
YoY Change	3779.71%	2239.79%	1351.56%
Total Long-Term Liabilities	$131.9K	$157.0K	$144.1K
YoY Change	3779.71%	22.27%	9.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.315M	$2.697M	$2.959M
Total Long-Term Liabilities	$131.9K	$157.0K	$144.1K
Total Liabilities	$2.447M	$2.854M	$3.104M
YoY Change	-31.09%	-24.31%	-74.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$113.2M	-$112.3M
YoY Change	7.71%	8.92%
Common Stock	$9.420K	$9.420K
YoY Change	0.03%	3.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.524M	$3.010M	$4.585M
YoY Change
Total Liabilities & Shareholders Equity	$3.971M	$5.865M	$7.688M
YoY Change	-63.8%	-47.18%	1084.83%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$2.004M	-$2.072M	-$2.028M
YoY Change	3.61%	12.26%	-8.59%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.488M	-$1.306M	-$2.862M
YoY Change	-17.39%	-36.26%	172.02%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-209.5K	-209.5K	$558.8K
YoY Change	-112.31%	-101.65%	-51.25%
NET CHANGE
Cash From Operating Activities	-1.488M	-1.306M	-$2.862M
Cash From Investing Activities	0.000	0.000	$0.00
Cash From Financing Activities	-209.5K	-209.5K	$558.8K
Net Change In Cash	-1.698M	-1.515M	-$2.303M
YoY Change	1600.12%	-114.2%	-2547.96%
FREE CASH FLOW
Cash From Operating Activities	-$1.488M	-$1.306M	-$2.862M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q2	zivo	Issuance Of Common Stock For Cash Amount IssuanceOfCommonStockForCashAmount	474970	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2067601	usd
CY2021Q2	zivo	Issuance Of Warrants Pursuant To The Participation Agreements IssuanceOfWarrantsPursuantToTheParticipationAgreements	14898	usd
CY2021Q2	zivo	Common Stock Issued On Cashless Warrant Exercise Amount CommonStockIssuedOnCashlessWarrantExerciseAmount	0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	6042209	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1749406	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4094116	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3832980	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	4238	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	18582	usd
	us-gaap	Interest Expense InterestExpense	6043	usd
	us-gaap	Interest Expense InterestExpense	43043	usd
CY2022Q2	zivo	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	9419660	shares
CY2022Q2	zivo	Interest Expense Related Parties InterestExpenseRelatedParties	0	usd
CY2021Q2	zivo	Interest Expense Related Parties InterestExpenseRelatedParties	77660	usd
	zivo	Interest Expense Related Parties InterestExpenseRelatedParties	0	usd
CY2021Q2	zivo	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	6490505	shares
	zivo	Interest Expense Related Parties InterestExpenseRelatedParties	188604	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001101026
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	9419660	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9419660	shares
CY2021Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	414000	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40449
	dei	Entity Registrant Name EntityRegistrantName	Zivo Bioscience, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0699977
	dei	Entity Address Address Line1 EntityAddressAddressLine1	21 E. Long Lake Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bloomfield Hills
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48304
	dei	City Area Code CityAreaCode	248
	dei	Local Phone Number LocalPhoneNumber	452 9866
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	ZIVO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9419660	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5083720	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8901875	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
	zivo	Employee And Director Equity Based Compensaton EmployeeAndDirectorEquityBasedCompensaton	1068373	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4238	usd
	us-gaap	Results Of Operations Revenue Other ResultsOfOperationsRevenueOther	0	usd
CY2021Q2	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	0	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	96242	usd
	us-gaap	Revenues Revenues	0	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1629553	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1281488	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2976295	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	7332972	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2718310	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	438048	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6043	usd
	zivo	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	9419660	shares
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	467918	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1117821	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1114670	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2067601	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	1749406	usd
	us-gaap	Operating Expenses OperatingExpenses	4094116	usd
	us-gaap	Operating Expenses OperatingExpenses	3832980	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	231647	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2071839	usd
	zivo	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	5846011	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-11423769	usd
CY2021Q2	zivo	Issuance Of Warrants For Services IssuanceOfWarrantsForServices	369965	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1845648	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4100159	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4064627	usd
CY2022Q2	zivo	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.22
CY2021Q2	zivo	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.28
	zivo	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.44
	zivo	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.70
CY2021Q2	zivo	Public Offering Issuance Of Stock And Warrants Amount PublicOfferingIssuanceOfStockAndWarrantsAmount	13800000	usd
	zivo	Fractional Shares From Split Amount FractionalSharesFromSplitAmount	0	usd
CY2021Q2	zivo	Underwriting And Other Expenses For Public Offering UnderwritingAndOtherExpensesForPublicOffering	-1622638	usd
CY2021Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4240	usd
CY2021Q2	zivo	Common Stock Issued On Conversion Of11 Convertible Debt And Accrued Interest Amount CommonStockIssuedOnConversionOf11ConvertibleDebtAndAccruedInterestAmount	7538556	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	22400	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1845648	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	7332972	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	4584518	usd
CY2022Q2	zivo	Employee And Director Equity Based Compensaton EmployeeAndDirectorEquityBasedCompensaton	497744	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2071839	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	3010423	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-11310614	usd
	zivo	Issuance Of Warrants For Services IssuanceOfWarrantsForServices	1344989	usd
	zivo	Issuance Of Common Stock For Cash Related Party Amount IssuanceOfCommonStockForCashRelatedPartyAmount	50000	usd
	zivo	Issuance Of Common Stock For Cash Amount IssuanceOfCommonStockForCashAmount	1514969	usd
	zivo	Issuance Of Warrants Pursuant To The Participation Agreements IssuanceOfWarrantsPursuantToTheParticipationAgreements	55697	usd
	zivo	Common Stock Issued On Cashless Warrant Exercise Amount CommonStockIssuedOnCashlessWarrantExerciseAmount	0	usd
	zivo	Public Offering Issuance Of Stock And Warrants Amount PublicOfferingIssuanceOfStockAndWarrantsAmount	13800000	usd
CY2021Q2	zivo	Fractional Shares From Split Amount FractionalSharesFromSplitAmount	0	usd
	zivo	Underwriting And Other Expenses For Public Offering UnderwritingAndOtherExpensesForPublicOffering	-1622638	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4240	usd
	zivo	Common Stock Issued On Conversion Of11 Convertible Debt And Accrued Interest Amount CommonStockIssuedOnConversionOf11ConvertibleDebtAndAccruedInterestAmount	7538557	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	22400	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4064627	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4100159	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	3010423	usd
	us-gaap	Profit Loss ProfitLoss	4100159	usd
	us-gaap	Profit Loss ProfitLoss	4064627	usd
	zivo	Amortization Of Lease Liability AmortizationOfLeaseLiability	41297	usd
	zivo	Amortization Of Lease Liability AmortizationOfLeaseLiability	10622	usd
	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	407085	usd
	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	0	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1068373	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1367389	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	459036	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	128661	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-246495	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-641281	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-17598	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-10851	usd
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-29058	usd
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	0	usd
	zivo	Increasedecreaseinadvanced Payments For Rd Obligations Participation Agreements IncreasedecreaseinadvancedPaymentsForRDObligationsParticipationAgreements	0	usd
	zivo	Increasedecreaseinadvanced Payments For Rd Obligations Participation Agreements IncreasedecreaseinadvancedPaymentsForRDObligationsParticipationAgreements	-85304	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-17616	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	281738	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4167377	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3100368	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	628600	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	190500	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	279378	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	127000	usd
	zivo	Proceeds From Public Sale Of Common Stock And Warrants ProceedsFromPublicSaleOfCommonStockAndWarrants	0	usd
	zivo	Proceeds From Public Sale Of Common Stock And Warrants ProceedsFromPublicSaleOfCommonStockAndWarrants	13804240	usd
	zivo	Expenses Related To The Public Offering ExpensesRelatedToThePublicOffering	0	usd
	zivo	Expenses Related To The Public Offering ExpensesRelatedToThePublicOffering	1622639	usd
	zivo	Proceeds From Sale Of Common Stock Warrants Participation Agreements ProceedsFromSaleOfCommonStockWarrantsParticipationAgreements	0	usd
	zivo	Proceeds From Sale Of Common Stock Warrants Participation Agreements ProceedsFromSaleOfCommonStockWarrantsParticipationAgreements	55697	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	50000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1514973	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	349222	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13865770	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3818155	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	10765402	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8901875	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	137862	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5083720	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10903264	usd
	us-gaap	Interest Paid InterestPaid	4853	usd
	us-gaap	Interest Paid InterestPaid	2056	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-112327200	usd
CY2020	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	820	usd
	zivo	Interest Due InterestDue	122520	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	243368	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	15178	usd
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	80000	usd
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	20000	usd
CY2022Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	20000	usd
CY2022Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	381000	usd
CY2021Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	281000	usd
CY2022Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	327000	usd
CY2021Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	187000	usd
CY2022Q2	zivo	Amortization Of The Rd Obligation AmortizationOfTheRDObligation	270000	usd
CY2021Q2	zivo	Amortization Of The Rd Obligation AmortizationOfTheRDObligation	0	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	644000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	520000	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	881000	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	595000	usd
	zivo	Amortization Of The Rd Obligation AmortizationOfTheRDObligation	407085	usd
	zivo	Amortization Of The Rd Obligation AmortizationOfTheRDObligation	0	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	497744	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	392365	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1068374	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1367389	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.3532	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0194	pure
CY2022Q2	zivo	Common Shares From Convertible Debentures And Related Accrued Interest CommonSharesFromConvertibleDebenturesAndRelatedAccruedInterest	53309	shares
CY2022Q2	zivo	Common Shares Issuable Upon The Exercise Of Outstanding Stock Options And Warrants CommonSharesIssuableUponTheExerciseOfOutstandingStockOptionsAndWarrants	6084205	shares
CY2021Q1	zivo	Common Shares From Convertible Debentures And Related Accrued Interest CommonSharesFromConvertibleDebenturesAndRelatedAccruedInterest	52839	shares
CY2021Q1	zivo	Common Shares Issuable Upon The Exercise Of Outstanding Stock Options And Warrants CommonSharesIssuableUponTheExerciseOfOutstandingStockOptionsAndWarrants	6344868	shares
CY2022Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	80000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	100000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	100000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	100000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	100000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2017Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	54993	usd
CY2017Q4	zivo	Operating Lease Commencement Date OperatingLeaseCommencementDate	2021-02-01
CY2017Q4	zivo	Rent Description RentDescription	Rent is $3,291 per month from January 15, 2021 to January 31, 2022 and $1,154 from February 1, 2022 to January 31, 2023.
CY2022Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	232464	usd
CY2022Q1	zivo	Operating Lease Commencement Date OperatingLeaseCommencementDate	2022-04-29
CY2022Q1	zivo	Rent Description RentDescription	Rent is $7,265 per month from commencement to November 30, 2022, $7,466 from November 30, 2022 to November 30, 2023, and $7,668 from November 30, 2023 to the lease end date.
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	231716	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	27225	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	86364	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	15178	usd
CY2022Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	157004	usd
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	0	usd
CY2022Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	240000	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	240000	usd
CY2022Q2	zivo	Total Debt And Accrued Interest Payable TotalDebtAndAccruedInterestPayable	337076	usd
CY2021Q4	zivo	Total Debt And Accrued Interest Payable TotalDebtAndAccruedInterestPayable	335486	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	27147	usd
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	6470	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	47291	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	12940	usd
	zivo	Operating Lease Weighted Average Remaining Lease Term OperatingLeaseWeightedAverageRemainingLeaseTerm	P2Y5M8D
CY2021	zivo	Operating Lease Weighted Average Remaining Lease Term OperatingLeaseWeightedAverageRemainingLeaseTerm	P1Y29D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.11	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.11	pure
	zivo	Cash Paid For Amounts Included In The Measurement Of Lease Liabilities CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities	23592	usd
	zivo	Non Cash Investment In Rou Asset NonCashInvestmentInRouAsset	241694	usd
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	50715	usd
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	116933	usd
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	11956	usd
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	279604	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	36236	usd
CY2022Q2	us-gaap	Capital Lease Obligations CapitalLeaseObligations	243368	usd
CY2022Q2	zivo	Operating Lease Liability Current Less Current Portion OperatingLeaseLiabilityCurrentLessCurrentPortion	86364	usd
CY2022Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	157004	usd
	zivo	Other Debt Description OtherDebtDescription	The Company’s 1% convertible debentures allow for rolling 30-day extensions until notice is given by the lender to the Company to the contrary.
CY2022Q2	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	97076	usd
CY2021Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	95486	usd
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	121700	usd
CY2020Q2	zivo	Paycheck Protection Program Loan Amount PaycheckProtectionProgramLoanAmount	121700	usd
CY2020Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.01	pure
CY2020Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.60	pure
CY2021Q3	zivo	Paycheck Protection Program Loan Amount PaycheckProtectionProgramLoanAmount	121700	usd
CY2021Q3	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	1653	usd
	zivo	Research And Development Expenses ResearchAndDevelopmentExpenses	270237	usd
CY2022Q2	zivo	Research And Development Expenses ResearchAndDevelopmentExpenses	67595	usd
	zivo	Contra Rd Expense Related To Personnel And Third Party Expenses ContraRDExpenseRelatedToPersonnelAndThirdPartyExpenses	407085	usd
	zivo	Contra Rd Expense Related To Personnel And Third Party Expenses ContraRDExpenseRelatedToPersonnelAndThirdPartyExpenses	0	usd
	zivo	Issuance Of Common Stock IssuanceOfCommonStock	54361	shares
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	8959953	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	95886	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	448409	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	467215	usd
	us-gaap	Results Of Operations Revenue Other ResultsOfOperationsRevenueOther	0	usd
CY2022Q2	us-gaap	Revenues Revenues	0	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	517114	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	58078	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	5600834	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	231716	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	27225	usd
CY2022Q2	us-gaap	Security Deposit SecurityDeposit	32058	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	3000	usd
CY2022Q2	us-gaap	Other Assets OtherAssets	263774	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	30225	usd
CY2022Q2	us-gaap	Assets Assets	5864608	usd
CY2021Q4	us-gaap	Assets Assets	8990178	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	407838	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	654333	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	86364	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	15178	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	349222	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	157004	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	usd
CY2022Q2	us-gaap	Liabilities Liabilities	2854185	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2947969	usd
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9419660	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	9420	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	115328203	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	114259830	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-112327200	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-108227041	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	3010423	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	6042209	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5864608	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8990178	usd
CY2022Q2	us-gaap	Results Of Operations Revenue Other ResultsOfOperationsRevenueOther	0	usd
CY2022Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	240000	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	240000	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	801061	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	1106320	usd
CY2022Q2	zivo	Deferred Rd Obligations Participation Agreements Related Parties DeferredRDObligationsParticipationAgreementsRelatedParties	267211	usd
CY2021Q4	zivo	Deferred Rd Obligations Participation Agreements Related Parties DeferredRDObligationsParticipationAgreementsRelatedParties	369037	usd
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	97076	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2697181	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2947969	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	157004	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	9420	usd
CY2021Q2	us-gaap	Results Of Operations Revenue Other ResultsOfOperationsRevenueOther	0	usd

Files In Submission

Name	View Source	Status
0001654954-22-010607-index-headers.html	Edgar Link	pending
0001654954-22-010607-index.html	Edgar Link	pending
0001654954-22-010607.txt	Edgar Link	pending
0001654954-22-010607-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zivo-20220630.xsd	Edgar Link	pending
zivo-20220630_cal.xml	Edgar Link	unprocessable
zivo-20220630_def.xml	Edgar Link	unprocessable
zivo-20220630_lab.xml	Edgar Link	unprocessable
zivo-20220630_pre.xml	Edgar Link	unprocessable
zivo_10q.htm	Edgar Link	pending
zivo_10q_htm.xml	Edgar Link	completed
zivo_ex311.htm	Edgar Link	pending
zivo_ex312.htm	Edgar Link	pending
zivo_ex321.htm	Edgar Link	pending
zivo_ex322.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZIVO
Zivo Bioscience, Inc. Stock $zivo

2022 Q3 Form 10-Q Financial Statement

#000165495422010607 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZIVO Zivo Bioscience, Inc. Stock $zivo

2022 Q3 Form 10-Q Financial Statement

#000165495422010607 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZIVO
Zivo Bioscience, Inc. Stock $zivo